BFRI Biofrontera Inc.
USHealthcareAs of 2026-07-10 16:00
Why BFRI matters now
Biofrontera Inc. (BFRI) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.10 with -3.51% on the session and $14.1M in market capitalization; recent performance reads 1-month +22.46% and YTD +73.16%.
The latest financial table shown here is Q1 2026, with revenue of $10.1M, net income of $-4.8M, and EPS of $-0.41. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -73.7%.
The latest indexable market news headline is "Biofrontera Inc. (BFRI) Shareholder/Analyst Call Prepared Remarks Transcript" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—; recent insider activity includes Leffler Eugene Frederick filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.90
P/S
0.29
EV/EBITDA
-1.40
DCF Value
$-32.97
FCF Yield
-73.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
82.8%
Operating Margin
-20.6%
Net Margin
-25.7%
ROE
-476.7%
ROA
-44.7%
ROIC
-62.1%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $10.1M | $-4.8M | $-0.41 |
| Q4 2025 | $17.1M | $5.6M | $0.48 |
| FY 2025 | $41.7M | $-10.5M | $-0.90 |
| Q3 2025 | $7.0M | $-6.6M | $-0.62 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
US
Exchange
—
Beta
0.85
Biofrontera Inc. is a biopharmaceutical enterprise dedicated to the marketing and distribution of pharmaceutical products within the United States, specifically targeting various dermatological conditions. The company's portfolio includes Ameluz, a prescribed medication designed for photodynamic therapy. This treatment, utilized in conjunction with its licensor's RhodoLED lamp series, addresses mild-to-moderate actinic keratosis on the face and scalp through both localized (lesion-directed) and broader area (field-directed) applications. Furthermore, Biofrontera offers Xepi, a prescription cream indicated for the treatment of impetigo. The firm was founded in 2015 and operates from its headquarters located in Woburn, Massachusetts.